TG Therapeutics price target raised to $20 from $15 at Roth Capital Roth Capital increased its price target on TG Therapeutics after the company announced data for its TG-1101 & ibrutinib combination in r/r CLL or MCL. The firm was quite impressed by the data and reiterates a Focus Pick rating on the shares.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
TG Therapeutics SPA for CLL study earlier than expected, says Ladenburg Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.